MCID: ESP027
MIFTS: 35

Esophagus Squamous Cell Carcinoma

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Esophagus Squamous Cell Carcinoma

MalaCards integrated aliases for Esophagus Squamous Cell Carcinoma:

Name: Esophagus Squamous Cell Carcinoma 12 15
Squamous Cell Carcinoma of Esophagus 12 73
Esophageal Squamous Cell Carcinoma 44
Scc of Esophagus 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3748
MeSH 44 C562729
NCIt 50 C4024
UMLS 73 C0279626

Summaries for Esophagus Squamous Cell Carcinoma

Disease Ontology : 12 An esophageal carcinoma that derives from epithelial squamous cells located in the esophagus.

MalaCards based summary : Esophagus Squamous Cell Carcinoma, also known as squamous cell carcinoma of esophagus, is related to gastric cardia adenocarcinoma and retinoblastoma. An important gene associated with Esophagus Squamous Cell Carcinoma is MIR296 (MicroRNA 296), and among its related pathways/superpathways is LncRNA-mediated mechanisms of therapeutic resistance. The drugs Cisplatin and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include lymph node, lung and liver.

Related Diseases for Esophagus Squamous Cell Carcinoma

Diseases related to Esophagus Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 99)
# Related Disease Score Top Affiliating Genes
1 gastric cardia adenocarcinoma 30.4 HOTAIR MEG3
2 retinoblastoma 30.2 BANCR HOTAIR MEG3
3 gastric cancer 30.0 AFAP1-AS1 BANCR HOTAIR MEG3
4 melanoma 29.9 BANCR HOTAIR MEG3
5 nasopharyngeal carcinoma 29.6 AFAP1-AS1 HOTAIR MEG3
6 lung cancer 29.5 AFAP1-AS1 BANCR HOTAIR MEG3
7 esophageal cancer 12.5
8 squamous cell carcinoma 10.6
9 hypoxia 10.5
10 gastric adenocarcinoma 10.5
11 papilloma 10.4
12 achalasia 10.2
13 body mass index quantitative trait locus 1 10.1
14 esophagitis 10.1
15 patulous eustachian tube 10.1
16 squamous cell papilloma 10.1
17 in situ carcinoma 10.1
18 tracheoesophageal fistula with or without esophageal atresia 10.1
19 leukemia 10.1
20 esophageal atresia 10.1
21 leiomyoma 10.1
22 megaesophagus 10.1
23 peptic esophagitis 10.1
24 gastritis 10.1
25 atrophic gastritis 10.1
26 functionless pituitary adenoma 10.0 HOTAIR MEG3
27 pituitary adenoma 10.0 HOTAIR MEG3
28 ovarian epithelial cancer 10.0 HOTAIR MEG3
29 tongue squamous cell carcinoma 10.0 AFAP1-AS1 MEG3
30 pancreatic ductal adenocarcinoma 10.0 AFAP1-AS1 HOTAIR
31 leiomyosarcoma 10.0
32 choriocarcinoma 10.0
33 colorectal adenocarcinoma 10.0
34 adenocarcinoma 10.0
35 lymphopenia 10.0
36 gastrointestinal system cancer 9.9 BANCR HOTAIR
37 breast cancer 9.9
38 small cell cancer of the lung 9.9
39 varicose veins 9.9
40 ataxia-telangiectasia 9.9
41 fanconi anemia, complementation group a 9.9
42 insulin-like growth factor i 9.9
43 squamous cell carcinoma, head and neck 9.9
44 xeroderma pigmentosum, variant type 9.9
45 tubulin, beta 9.9
46 papillary thyroid microcarcinoma 9.9
47 cervical cancer 9.9
48 pyogenic sterile arthritis, pyoderma gangrenosum, and acne 9.9
49 aplastic anemia 9.9
50 hepatitis c virus 9.9

Graphical network of the top 20 diseases related to Esophagus Squamous Cell Carcinoma:



Diseases related to Esophagus Squamous Cell Carcinoma

Symptoms & Phenotypes for Esophagus Squamous Cell Carcinoma

Drugs & Therapeutics for Esophagus Squamous Cell Carcinoma

Drugs for Esophagus Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 149)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
2
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
3
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
4
Irinotecan Approved, Investigational Phase 3,Phase 2,Phase 1 100286-90-6, 97682-44-5 60838
5
Fluorouracil Approved Phase 3,Phase 2,Phase 1,Not Applicable 51-21-8 3385
6
Capecitabine Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 154361-50-9 60953
7
Cetuximab Approved Phase 2, Phase 3,Phase 3,Phase 1 205923-56-4 56842117 2333
8
Oxaliplatin Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 61825-94-3 43805 6857599 5310940 9887054
9
leucovorin Approved Phase 2, Phase 3,Phase 3,Phase 1 58-05-9 6006 143
10
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 114977-28-5 148124
11
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
12
Levoleucovorin Approved, Investigational Phase 2, Phase 3,Phase 1 68538-85-2
13
Gefitinib Approved, Investigational Phase 3,Phase 2,Phase 1 184475-35-2 123631
14
Nedaplatin Approved, Investigational Phase 3,Phase 2,Phase 1 95734-82-0
15
Vinblastine Approved Phase 3 865-21-4 241903 13342
16
Vinorelbine Approved, Investigational Phase 3,Phase 2 71486-22-1 60780 44424639
17
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
18
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
19
Nivolumab Approved Phase 3,Phase 1,Phase 2 946414-94-4
20
Trioxsalen Approved Phase 3 3902-71-4 5585
21
Pembrolizumab Approved Phase 3,Phase 2,Phase 1 1374853-91-4
22
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3,Phase 1 59-30-3 6037
23
Camptothecin Experimental Phase 3,Phase 2,Phase 1 7689-03-4
24
Caffeic acid Experimental, Investigational Phase 3 331-39-5 1549111
25
s 1 (combination) Phase 3,Phase 2
26 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Not Applicable
27 Antimitotic Agents Phase 3,Phase 2,Phase 1,Not Applicable
28 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1,Not Applicable
29 Analgesics Phase 3,Phase 2
30 Tea Phase 3
31 Fibrinolytic Agents Phase 3
32 Anti-Inflammatory Agents, Non-Steroidal Phase 3,Phase 2
33 Analgesics, Non-Narcotic Phase 3,Phase 2
34 Anti-Inflammatory Agents Phase 3,Phase 2
35 Antirheumatic Agents Phase 3,Phase 2
36 Antipyretics Phase 3
37 Peripheral Nervous System Agents Phase 3,Phase 2
38 Cyclooxygenase Inhibitors Phase 3,Phase 2
39 Platelet Aggregation Inhibitors Phase 3,Phase 2
40 topoisomerase I inhibitors Phase 3,Phase 2,Phase 1
41 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
42 Antimetabolites Phase 3,Phase 2,Phase 1,Not Applicable
43 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
44 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Not Applicable
45 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
46 Vitamin B9 Phase 2, Phase 3,Phase 1
47 Vitamins Phase 2, Phase 3,Phase 1
48 Folate Phase 2, Phase 3,Phase 1
49 Trace Elements Phase 2, Phase 3,Phase 1,Not Applicable
50 Vitamin B Complex Phase 2, Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 284)
# Name Status NCT ID Phase Drugs
1 Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell Carcinoma Unknown status NCT02677597 Phase 3 Cisplatin Combined With S-1;Cisplatin Combined With Paclitaxel
2 Chemoradiation With or Without Nimotuzumab in Treating Esophageal Cancer Patients Who Suffer With Recurrence in Regional Lymph Nodes After Esophagectomy Unknown status NCT01402180 Phase 2, Phase 3 chemotherapy;chemotherapy
3 Chemoprevention of Esophageal Squamous Cell Carcinoma (ESCC) With Aspirin and Tea Polyphenols Unknown status NCT01496521 Phase 3 Aspirin
4 Is ENI Necessary For Patients With Thoracic Esophageal Cancer After Esophagectomy And With Pathological Stage Of T1-2,N+,M0 Unknown status NCT01398449 Phase 3
5 Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Cancer: ESWN 01 Trial Unknown status NCT02319187 Phase 3 S1;S-1;irinotecan
6 Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus Unknown status NCT00002884 Phase 3 chemotherapy;cisplatin;fluorouracil
7 Cisplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients With Esophageal Cancer Unknown status NCT00509561 Phase 2, Phase 3 capecitabine;cisplatin
8 A Phase III Study of Comparing Paclitaxel Plus 5-Fluorouracil Versus Cisplatin Plus 5-Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Carcinoma Completed NCT01591135 Phase 3 Paclitaxel plus 5-fluorouracil;Cisplatin plus 5-fluorouracil
9 Surgery With or Without Chemotherapy in Treating Patients With Stage II or Stage III Cancer of the Esophagus Completed NCT00002897 Phase 3 cisplatin;fluorouracil
10 Surgery With or Without Radiation Therapy and Chemotherapy in Treating Patients With Esophageal Cancer Completed NCT00047112 Phase 3 cisplatin;fluorouracil
11 Surgery or Chemoradiation for Esophageal Cancer Completed NCT01032967 Phase 3
12 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Cancer of the Esophagus Completed NCT00002631 Phase 3 chemotherapy;cisplatin;fluorouracil
13 Surgery With or Without Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus Completed NCT00003118 Phase 3 cisplatin;fluorouracil
14 Radiation Therapy + Combination Chemotherapy as 1st-Line Therapy for Patients With Inoperable Esophageal Cancer Completed NCT00861094 Phase 2, Phase 3 cisplatin;5-FU;oxaliplatin;Folinic Acid
15 Gefitinib in Treating Patients With Esophageal Cancer That is Progressing After Chemotherapy Completed NCT01243398 Phase 3
16 Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery Completed NCT01107639 Phase 3 cisplatin;docetaxel
17 Postoperative Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Patients With Locoregionally Advanced Esophageal Squamous Cell Carcinoma Recruiting NCT03600831 Phase 2, Phase 3 Docetaxel plus cisplatin
18 Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma Recruiting NCT02611700 Phase 3 Nimotuzumab;Paclitaxel;Cisplatin;Placebo
19 A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as First Line Treatment in Patients With Advanced Esophageal Squamous Cell Carcinoma Recruiting NCT03783442 Phase 3 Platinum (cisplatin or oxaliplatin) + Fluorouracil (5-FU);Platinum (cisplatin or oxaliplatin) + capecitabine;Platinum (cisplatin or oxaliplatin) + paclitaxel
20 A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Esophageal Squamous Cell Carcinoma Recruiting NCT03430843 Phase 3 BGB-A317;Paclitaxel, or Docetaxel, or Irinotecan
21 A Comparison of Paclitaxel-based Three Regimens Concurrent With Radiotherapy for Patients With Local Advanced Esophageal Cancer Recruiting NCT02459457 Phase 3 Paclitaxel and Cisplatin;Paclitaxel and Fluorouracil;Paclitaxel and Carboplatin
22 A Phase III Trail of Adjuvant Chemoradiotherapy Versus Adjuvant Radiotherapy in Esophageal Squamous Cell Carcinoma Recruiting NCT02570893 Phase 3 Paclitaxel and carboplatin
23 Neoadjuvant Chemotherapy Versus Surgery Alone for Esophageal Squamous Cell Carcinoma Recruiting NCT02395705 Phase 3 cisplatin and paclitaxel
24 A Phase III Study of Nimotuzumab Plus Concurrent Chemoradiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma Recruiting NCT02409186 Phase 3 Nimotuzumab;chemoradiotherapy Paclitaxel;chemoradiotherapy Cisplatin
25 Adjuvant Chemotherapy With Paclitaxel and Cisplatin in Lymph Node-Positive Adjuvant Chemotherapy in the Treatment of the Lymph Node Positive Thoracic Esophageal Squamous Cell Carcinoma Recruiting NCT02461043 Phase 3 paclitaxel; cisplatin
26 Improve the Treatment of Thoracic Esophageal Cancer Recruiting NCT01137123 Phase 3 adjuvant chemotherapy
27 Comparing Paclitaxel/Cisplatin and Cisplatin/5-fluorouracil in Neo-CRT for ESCC Recruiting NCT03623737 Phase 2, Phase 3 neoadjuvant chemoradiation
28 Comparing 61.2 Gy Radiotherapy Dose Versus 50.4 Gy Radiotherapy Dose for Locally Advanced Esophageal Carcinoma Recruiting NCT03790553 Phase 3
29 Different Cycles of Cisplatin-5-fluorouracil for the Chemoradiotherapy of Esophageal Squamous Cancer Recruiting NCT02607540 Phase 3
30 Chemoradiotherapy of Capecitabine With or Without Oxaliplatin Versus Cisplatin-5-FU for Esophageal Squamous Cancer Recruiting NCT02025036 Phase 3 Capecitabine(Aibin);Oxaliplatin(Aiheng)
31 The Role of Different Cycles of Chemotherapy(Capecitabine-oxaliplatin) in Esophageal Chemoradiotherapy Recruiting NCT02604615 Phase 3 Capecitabine(Aibin);Oxaliplatin(Aiheng)
32 Study of Docetaxel or Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Esophageal Cancer Recruiting NCT02465736 Phase 3 Docetaxel;Cisplatin;Vinorelbine;Cisplatin
33 Efficacy of Intensity Modulated Radiation Therapy After Surgery in Early Stage of Esophageal Carcinoma; Recruiting NCT01745107 Phase 3
34 Chemoradiotherapy With or Without Enteral Nutrition for Locally Advanced Thoracic Esophageal Carcinoma Recruiting NCT02399306 Phase 3 Enteral nutrition
35 Adjuvant Therapies or Surgery Alone for High Risk pN0 Esophageal Cancer Recruiting NCT02891083 Phase 3 Adjuvant chemotherapy (Paclitaxel and Cisplatin)
36 Effect of Megestrol Acetate on the Quality of Life of Patients With Esophageal Carcinoma Recruiting NCT02644408 Phase 3 Megestrol(Yining)
37 Different Cycles of Capecitabine Usage in Esophageal Cancer Concurrent Chemoradiotherapy Recruiting NCT02603159 Phase 3 Capecitabine(Aibin)
38 S-1 Concurrent With Radiotherapy Versus Radiotherapy for Elderly Patients With Esophageal Cancer Recruiting NCT02813967 Phase 3 S-1
39 Robot-assisted Esophagectomy Versus Conventional Thoracoscopic Esophagectomy Recruiting NCT03094351 Phase 3
40 A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin Recruiting NCT03143153 Phase 3 Cisplatin;Fluorouracil
41 Simultaneous Modulated Accelerated Boost Versus Standard Dose Radiotherapy in Esophageal Cancer Recruiting NCT02556762 Phase 3 PF
42 Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients Recruiting NCT03731442 Phase 3 Paclitaxel;Platinum;PEG-rhG-CSF
43 Clinical Study of Time Optimizing of Endoscopic Photodynamic Therapy on Esophageal and/or Gastric Cardiac Cancer Recruiting NCT02628665 Phase 3 photosensitizer(photofrin)
44 Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181) Active, not recruiting NCT02564263 Phase 3 paclitaxel;docetaxel;irinotecan
45 Phase III Study of Neo-adjuvant Chemoradiotherapy Followed by Surgery for Squamous Cell Esophageal Cancer Active, not recruiting NCT01216527 Phase 3
46 Study of SHR-1210 Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal Cancer Active, not recruiting NCT03099382 Phase 3 Docetaxel;Irinotecan
47 Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer Active, not recruiting NCT00655876 Phase 3 cetuximab;cisplatin;paclitaxel
48 The Efficacy and Safety of Caffeic Acid for Esophageal Cancer Enrolling by invitation NCT03070262 Phase 3 CA;placebo group
49 Sintilimab or Placebo With Paclitaxel and Cisplatin in Esophageal Squamous Cell Carcinoma Not yet recruiting NCT03748134 Phase 3 Paclitaxel;Cisplatin
50 Adjuvant Radiotherapy for Esophageal Squamous Cell Carcinoma With Positive Circumstantial Resection Margin Not yet recruiting NCT03273647 Phase 3

Search NIH Clinical Center for Esophagus Squamous Cell Carcinoma

Cochrane evidence based reviews: esophageal squamous cell carcinoma

Genetic Tests for Esophagus Squamous Cell Carcinoma

Anatomical Context for Esophagus Squamous Cell Carcinoma

MalaCards organs/tissues related to Esophagus Squamous Cell Carcinoma:

41
Lymph Node, Lung, Liver, Bone, Thyroid, Breast, Bone Marrow

The Foundational Model of Anatomy Ontology organs/tissues related to Esophagus Squamous Cell Carcinoma:

19
The Esophagus

Publications for Esophagus Squamous Cell Carcinoma

Articles related to Esophagus Squamous Cell Carcinoma:

(show top 50) (show all 58)
# Title Authors Year
1
Targeting Orai1-mediated store-operated calcium entry by RP4010 for anti-tumor activity in esophagus squamous cell carcinoma. ( 29908962 )
2018
2
Clinic implication of MUC1 O-glycosylation and C1GALT1 in esophagus squamous cell carcinoma. ( 30076562 )
2018
3
Comparison of the effect of postoperative radiotherapy with surgery alone for esophagus squamous cell carcinoma patients: A meta-analysis. ( 30461614 )
2018
4
Long noncoding RNA HAND2-AS1 inhibits cancer cell proliferation, migration, and invasion in esophagus squamous cell carcinoma by regulating microRNA-21. ( 30520131 )
2018
5
Considering the downregulation of Tpm1.6 and Tpm1.7 in squamous cell carcinoma of esophagus as a potent biomarker. ( 30259780 )
2018
6
The impact of pathological complete response after neoadjuvant chemoradiotherapy in locally advanced squamous cell carcinoma of esophagus. ( 29066057 )
2018
7
Endoscopic diagnosis and management of early squamous cell carcinoma of esophagus. ( 28815064 )
2017
8
Kaempferol inhibits cell proliferation and glycolysis in esophagus squamous cell carcinoma via targeting EGFR signaling pathway. ( 26831667 )
2016
9
Pretreatment lymphopenia is an easily detectable predictive and prognostic marker in patients with metastatic esophagus squamous cell carcinoma receiving first-line chemotherapy. ( 26814381 )
2016
10
Amplification and overexpression of CTTN and CCND1 at chromosome 11q13 in Esophagus squamous cell carcinoma (ESCC) of North Eastern Chinese Population. ( 27877079 )
2016
11
Genotypes of CYP1A1,a88SULT1A1 and SULT1A2 and risk of squamous cell carcinoma of esophagus: outcome of a case-control study from Kashmir, India. ( 26455829 )
2016
12
MiR-205 functions as a tumor suppressor in adenocarcinoma and an oncogene in squamous cell carcinoma of esophagus. ( 26711784 )
2016
13
Multiple Meningocerebral Metastasis and Extensive Skull Metastasis from Squamous Cell Carcinoma of Esophagus: A Case Report and Review of Literature. ( 27867927 )
2016
14
Diagnostic and prognostic potential of miR-21, miR-29c, miR-148 and miR-203 in adenocarcinoma and squamous cell carcinoma of esophagus. ( 25928282 )
2015
15
Leu432Val Polymorphism of CYP1B1 is Not Associated with Squamous Cell Carcinoma of Esophagus--a Case-Control Study from Kashmir, India. ( 26225675 )
2015
16
Outcomes of patients with squamous cell carcinoma of esophagus who did not receive surgical resection after neoadjuvant radiochemotherapy. ( 25908044 )
2015
17
Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus: A Phase III Randomized Trial. ( 26287319 )
2015
18
Prognostic value of metastatic lymph nodal ratio in squamous cell carcinoma of esophagus: A three-step extrapolative study. ( 25422807 )
2014
19
Role of postoperative radiotherapy for microscopic margin involvement in the squamous cell carcinoma of esophagus. ( 24155679 )
2013
20
Prognostic Value of Tumor-Infiltrating Mast Cells in Outcome of Patients with Esophagus Squamous Cell Carcinoma. ( 24091743 )
2013
21
Human papillomavirus types 16 and 18 in esophagus squamous cell carcinoma: a meta-analysis. ( 23916383 )
2013
22
A phase II study of oxaliplatin in combination with leucovorin and fluorouracil as first-line chemotherapy in patients with metastatic squamous cell carcinoma of esophagus. ( 23370661 )
2013
23
Adverse effects of preserved vegetables on squamous cell carcinoma of esophagus and precancer lesions in a high risk area. ( 23621214 )
2013
24
Dermatan sulfate is involved in the tumorigenic properties of esophagus squamous cell carcinoma. ( 22350411 )
2012
25
Prediagnostic smoking and postoperative survival in lymph node-negative esophagus squamous cell carcinoma patients. ( 22913634 )
2012
26
[A multi-centered randomized controlled study of neo-adjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of esophagus: an interim analysis]. ( 22781642 )
2012
27
Downregulation of tropomyosin-1 in squamous cell carcinoma of esophagus, the role of Ras signaling and methylation. ( 22965424 )
2012
28
Retrospective study of gemcitabine based chemotherapy for unresectable or recurrent esophagus squamous cell carcinoma refractory to first line chemotherapy. ( 23098537 )
2012
29
A phase I dose escalation study of Nimotuzumab in combination with concurrent chemoradiation for patients with locally advanced squamous cell carcinoma of esophagus. ( 21901403 )
2012
30
Parotid gland metastasis from squamous cell carcinoma of esophagus detected by FDG PET/CT. ( 22955076 )
2012
31
Use of pretreatment metabolic tumor volumes on PET-CT to predict the survival of patients with squamous cell carcinoma of esophagus treated by curative surgery. ( 22993379 )
2012
32
Analysis of the RUNX3 gene methylation in serum DNA from esophagus squamous cell carcinoma, gastric and colorectal adenocarcinoma patients. ( 22234069 )
2011
33
Mimicry of physiological urinary FDG excretion: squamous cell carcinoma of esophagus metastasizing to psoas muscle. ( 21157206 )
2011
34
MDM2 is overexpressed and regulated by the eukaryotic translation initiation factor 4E (eIF4E) in human squamous cell carcinoma of esophagus. ( 21080085 )
2011
35
Role of preoperative chemotherapy in squamous cell carcinoma of esophagus in kashmir, a cancer belt - a pilot study. ( 21545214 )
2011
36
Squamous cell carcinoma of esophagus in a 15-year-old boy. ( 20975784 )
2010
37
Reduced axin protein expression is associated with a poor prognosis in patients with squamous cell carcinoma of esophagus. ( 19582507 )
2009
38
Positive impact of radiation dose on disease free survival and locoregional control in postoperative radiotherapy for squamous cell carcinoma of esophagus. ( 19021683 )
2009
39
Numb chin syndrome as a manifestation of metastatic squamous cell carcinoma of esophagus. ( 19293491 )
2009
40
Evaluation of visualization of squamous cell carcinoma of esophagus and pharynx using an autofluorescence imaging videoendoscope system. ( 19780882 )
2009
41
[Transforming growth factor beta1 regulation of epithelial-mesenchymal transition in esophagus squamous cell carcinoma]. ( 19094466 )
2008
42
Concurrent chemoradiotherapy or endoscopic stenting for advanced squamous cell carcinoma of esophagus: a case-control study. ( 18057993 )
2008
43
Choriocarcinoma - a rare association with squamous cell carcinoma of esophagus. ( 16567899 )
2006
44
Human papillomavirus in squamous cell carcinoma of esophagus in a high-risk population. ( 15754405 )
2005
45
Squamous cell carcinoma of esophagus masquerading as solitary thyroid nodule. ( 16391440 )
2005
46
[The effect of postoperative chemotherapy after esophagectomy on the survival rate to patients with original squamous cell carcinoma of esophagus]. ( 15231207 )
2004
47
Umbilical metastasis with squamous cell carcinoma of esophagus. ( 15333983 )
2004
48
Colonic metastasis from squamous cell carcinoma of esophagus. ( 12416763 )
2002
49
Gene expression profile changes in initiation and progression of squamous cell carcinoma of esophagus. ( 11169949 )
2001
50
Efficacy of computed axial tomography in the evaluation of the involvement of the respiratory tract in patients with squamous cell carcinoma of esophagus. ( 10631912 )
1999

Variations for Esophagus Squamous Cell Carcinoma

Expression for Esophagus Squamous Cell Carcinoma

Search GEO for disease gene expression data for Esophagus Squamous Cell Carcinoma.

Pathways for Esophagus Squamous Cell Carcinoma

Pathways related to Esophagus Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 9.7 HOTAIR MEG3

GO Terms for Esophagus Squamous Cell Carcinoma

Sources for Esophagus Squamous Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....